Two leading biotech companies announced a multi-million-dollar collaboration to develop the first large-scale AI foundation model specifically designed to understand aging biology and enable predictive healthcare. Insilico Medicine and Human Life Foundation Models (HLFM), a newly launched company established by Human Longevity, Inc., are joining forces to create what they call a "super-intelligence" AI system capable of decoding the biological mechanisms of aging and identifying disease risks before symptoms appear.

The partnership arrives at a pivotal moment for longevity science. According to recent analysis by UBS, the global longevity market is currently valued at approximately $5.3 trillion and is projected to reach $8 trillion by 2030. This explosive growth reflects a fundamental shift in how the world thinks about aging, moving it from a niche scientific curiosity to a major economic and healthcare priority as aging populations reshape global labor markets and consumer demand.

What Makes This AI Model Different From Existing Healthcare AI?

The jointly developed foundation model will combine two powerful assets. Insilico brings its expertise in multimodal foundation model development and deep learning system engineering, along with its advanced training and evaluation capabilities called MMAI Gym. HLFM will integrate these tools with Human Longevity's unique, de-identified multi-omic and clinical datasets spanning over a decade of research.

Human Longevity has assembled one of the world's most comprehensive integrated datasets, drawing from multi-omics data, imaging scans, and longitudinal health records from thousands of individuals. By fusing advanced algorithms with this deep biological data, the foundation models are expected to detect, diagnose, and manage patient conditions with clinical-grade precision, enabling early detection of age-related diseases and discovery of novel AI-driven therapeutics.

"By combining Insilico's expertise in generative AI drug discovery and multimodal foundation models with HLFM's unique datasets, and conducting rigorous model training and benchmark evaluation under the advanced MMAI Gym framework, we aim to build a next-generation AI system capable of decoding the biology of aging," said Alex Zhavoronkov, Founder, CEO and Chief Business Officer of Insilico Medicine.

Alex Zhavoronkov, Founder, CEO and Chief Business Officer of Insilico Medicine

How Could This AI Foundation Model Transform Patient Care?

• Early Disease Detection: The model is designed to identify disease risks decades before symptoms appear, shifting healthcare from treating existing conditions to preventing them from developing in the first place.
• Personalized Interventions: By analyzing individual biological data, the AI can recommend targeted therapies and lifestyle interventions tailored to each person's unique aging biology and disease risk profile.
• Accelerated Drug Discovery: AI-driven identification of novel therapeutic targets could dramatically reduce the time and cost of developing longevity-focused treatments, potentially lowering drug prices for consumers.
• Reduced Genetic Testing Burden: Recent research shows AI can reliably detect certain genetic mutations from standard pathology slides, potentially reducing the need for rapid genetic testing by more than 40 percent and preserving limited tissue samples for more comprehensive sequencing.

The broader context of AI in healthcare supports this optimistic outlook. A recent review found that AI is transforming oncology care by enhancing diagnostic precision in pathology, accelerating clinical trial matching, and enabling personalized treatment strategies. One study investigated a tool called EGFR AI Genomic Lung Evaluation (EAGLE), which predicts EGFR mutational status from diagnostic biopsies of patients with lung adenocarcinoma using standard pathology slides. The results showed that AI could reliably detect EGFR mutations, potentially reducing the need for rapid genetic testing by more than 40 percent.

Why Is AI Drug Discovery Becoming Central to Longevity Research?

Longevity has been central to Insilico's mission since its inception. The company gained industry attention in 2015 when founder Alex Zhavoronkov challenged the tech world at the NVIDIA GTC conference with a provocative question: "Can NVIDIA cure aging?" Recently, Insilico announced the industry's first longevity board composed of high-profile scientists and chaired by Andrew Adams, PhD, Group Vice President of Molecular Discovery at Eli Lilly and Company, to accelerate AI-driven aging research for drug discovery.

Insilico has published over 50 research papers related to aging and longevity research, biomarkers of aging, therapeutic targets, and therapeutics implicated in aging and longevity since 2014. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

AI's role in drug discovery extends beyond longevity. Developing new drugs is notoriously expensive and time-consuming, costing up to $2.6 billion and taking 12 to 14 years through traditional methods. AI helps by speeding up drug development, cutting costs, improving returns, and potentially lowering prices for consumers. Pharmaceutical companies have many potential compounds to fight diseases but lack efficient tools to identify the most promising candidates. AI excels at this task, analyzing vast chemical and biological datasets to predict which compounds are most likely to work.

"Human Longevity was founded with the vision that large-scale biological data combined with artificial intelligence would fundamentally transform medicine," stated Wei-Wu He, Executive Chairman of Human Longevity.

Wei-Wu He, Executive Chairman of Human Longevity

What Does This Mean for the Future of Medicine?

The companies believe that these advancements will play a pivotal role in the future of medicine by shifting the global healthcare paradigm from reactive disease treatment toward proactive and preventive longevity science. Rather than waiting for patients to develop heart disease, cancer, or Alzheimer's and then treating them, doctors could use AI-powered predictions to intervene years or decades earlier, when prevention is far more effective and less costly.

The foundation models are expected to be commercially available to drive breakthroughs in early detection of age-related diseases, predictive health risk modeling, and discovery of novel AI-driven therapeutics and personalized interventions to extend healthy human lifespan. This represents a fundamental reimagining of how medicine works, moving from a system designed to treat the sick to one designed to keep people healthy as they age.

The collaboration between Insilico and HLFM signals that the longevity field is maturing rapidly. What was once considered science fiction is becoming clinical reality, backed by billions in investment and the combined expertise of leading biotech companies and research institutions.